CEO Hamid Erfanian resigns; COO Kara Cannon named Interim CEO

ENZO BIOCHEM INC

CEO Hamid Erfanian resigned effective Sep 5, 2023; final employment date Nov 18, 2023.
Severance: $624k base (12 months), $187.2k bonus, $1.5M restricted stock grant, accelerated RSUs & options.
COO Kara Cannon appointed Interim CEO; base salary increased from $308k to $350k.
Company shifts focus to life sciences division after divestiture of Enzo Clinical Lab.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Hamid Erfanian

Chief Executive Officer

ENZO BIOCHEM INC

Effective: 2023-09-05
Successor: Kara Cannon
Filed: September 7, 2023, 7:59 PM ET

On September 5, 2023, Enzo Biochem, Inc. (the “Company”) entered into a Separation Agreement and General Release (the “Separation Agreement”) with Hamid Erfanian, the Company’s Chief Executive Officer, which provides for Mr. Erfanian’s separation of employment, resignations from his positions as Chief Executive Officer and as a director of the Company

Appointed (interim)

Kara Cannon

Interim Chief Executive Officer

ENZO BIOCHEM INC

Effective: 2023-09-05
Filed: September 7, 2023, 7:59 PM ET

the Company’s board of directors appointed Kara Cannon, the Company’s Chief Operating Officer, to serve as Interim Chief Executive Officer of the Company, effective immediately upon Mr. Erfanian’s resignation as Chief Executive Officer

Departed

Hamid Erfanian

Director

ENZO BIOCHEM INC

Effective: 2023-09-05
Filed: September 7, 2023, 7:59 PM ET

Pursuant to the Separation Agreement, Mr. Erfanian’s resignations as Chief Executive Officer and as a director are effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hamid Erfanian resigned as Chief Executive Officer at ENZO BIOCHEM INC.

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On September 5, 2023, Enzo Biochem, Inc. (the “Company”) entered into a Separation Agreement and General Release (the “Separation Agreement”) with Hamid Erfanian, the Company’s Chief Executive Officer, which provides for Mr. Erfanian’s separation of employment, resignations from his positions as Chief Executive Officer and as a director of the Company

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Kara Cannon was appointed as Interim Chief Executive Officer at ENZO BIOCHEM INC.

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

the Company’s board of directors appointed Kara Cannon, the Company’s Chief Operating Officer, to serve as Interim Chief Executive Officer of the Company, effective immediately upon Mr. Erfanian’s resignation as Chief Executive Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Hamid Erfanian resigned as Director at ENZO BIOCHEM INC.

Action: resigned
Role: Director

Exact text from the filing

Pursuant to the Separation Agreement, Mr. Erfanian’s resignations as Chief Executive Officer and as a director are effective immediately

View on SEC.gov

Source: SEC EDGAR

accession 0001213900-23-074469

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.